The U.S. Food and Drug Administration (FDA) has announced updated labeling requirements for all extended-release ADHD medications, including amphetamine and methylphenidate formulations. This change aims to highlight the risk of significant weight loss and other adverse effects in children under 6 years old.
Key Points on ADHD Medication and Weight Loss Risk
Extended-release stimulant medications are not currently approved for children younger than 6, but some healthcare providers prescribe them off-label. Clinical studies reveal that younger children experience higher drug levels in their bloodstream and more frequent side effects compared to older children. Notably, weight loss in this age group can be clinically significant and potentially harmful.
What the New Labeling Includes
The FDA now mandates a “Limitation of Use” section in the prescribing information for these medications. This section will explicitly warn about:
- Increased drug exposure in children under 6 years
- Elevated rates of adverse reactions, including weight loss
Recommendations for Healthcare Providers and Parents
Healthcare professionals should closely monitor growth and development in young children prescribed extended-release stimulants. If weight loss occurs, they should consider alternative treatments such as immediate-release stimulants or behavioral therapies. Early intervention can help mitigate negative health impacts.
Parents and caregivers observing weight loss in their child taking these medications are advised to consult their pediatrician promptly to evaluate the risks and benefits of continuing treatment.
Practical Advice for Families
Track your child’s weight and growth regularly during ADHD treatment
Communicate any concerns about appetite or weight changes with your healthcare provider
Explore behavioral therapy options alongside or instead of medication
By staying informed and vigilant, families and healthcare providers can better manage ADHD treatment while safeguarding children’s overall health.
Related topics:
